TNF and TNFR polymorphisms in severe sepsis and septic shock: A prospective multicentre study

Genes and Immunity

Volumn 5, Issue 8, 2004, Pages 631-640

  Gordon, A C ^a   Lagan, A L ^b   Aganna, E ^a   Cheung, L ^c   Peters, C J ^a   McDermott, M F ^a   Millo, J L ^d   Welsh, K I ^b   Holloway, P ^d   Hitman, G A ^a   Piper, R D ^c   Garrard, C S ^d   Hinds, C J ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c UNIVERSITY OF SYDNEY   (Australia)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Haplotypes; Polymorphisms; Sepsis; Septic shock; TNF; TNF receptors

Indexed keywords

TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; AUSTRALIA; BLOOD LEVEL; CAUCASIAN; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE PREDISPOSITION; DISEASE SEVERITY; DNA POLYMORPHISM; FEMALE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC CODE; HAPLOTYPE; HUMAN; INTENSIVE CARE UNIT; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK; SURVIVAL; UNITED KINGDOM;

AUSTRALIA; DNA PRIMERS; ENGLAND; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; MALE; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SEPSIS; SHOCK, SEPTIC; TUMOR NECROSIS FACTOR DECOY RECEPTORS;

EID: 19944369381     PISSN: 14664879     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gene.6364136     Document Type: Article

References (59)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303-1310.
2. Sands KE, Bates DW, Lanken PN et al. Epidemiology of sepsis syndrome in 8 academic medical centers. Academic Medical Center Consortium Sepsis Project Working Group. JAMA 1997; 278: 234-240.
3. Brun-Buisson C, Doyon F, Carlet J et al. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA 1995; 274: 968-974.
4. Fisher CJ, Agosti JM, Opal SM et al. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N Engl J Med 1996; 334: 1697-1702.
5. Bernard GR, Vincent JL, Laterre PF et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
6. Sorensen TI, Nielsen GG, Andersen PK, Teasdale TW. Genetic and environmental influences on premature death in adult adoptees. N Engl J Med 1988; 318: 727-732.
7. Mira JP, Cariou A, Grall F et al. Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. JAMA 1999; 282: 561-568.
8. Appoloni O, Dupont E, Vandercruys M, Andriens M, Duchateau J, Vincent JL. Association of tumor necrosis factor-2 allele with plasma tumor necrosis factor-alpha levels and mortality from septic shock. Am J Med 2001; 110: 486-488.
9. Stuber F, Petersen M, Bokelmann F, Schade U. A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. Crit Care Med 1996; 24: 381-384.
10. Majetschak M, Flohe S, Obertacke U et al. Relation of a TNF gene polymorphism to severe sepsis in trauma patients. Ann Surg 1999; 230: 207-214.
11. Lowe PR, Galley HF, Abdel-Fattah A, Webster NR. Influence of interleukin-10 polymorphisms on interleukin-10 expression and survival in critically ill patients. Crit Care Med 2003; 31: 34-38.
12. Ma P, Chen D, Pan J, Du B. Genomic polymorphism within interleukin-1 family cytokines influences the outcome of septic patients. Crit Care Med 2002; 30: 1046-1050.
13. Hubacek JA, Stuber F, Frohlich D et al. Gene variants of the bactericidal/permeability increasing protein and lipopolysaccharide binding protein in sepsis patients: gender-specific genetic predisposition to sepsis. Crit Care Med 2001; 29: 557-561.
14. Gibot S, Cariou A, Drouet L, Rossignol M, Ripoll L. Association between a genomic polymorphism within the CD14 locus and septic shock susceptibility and mortality rate. Crit Care Med 2002; 30: 969-973.
15. Hermans PW, Hibberd ML, Booy R et al. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group. Lancet 1999; 354: 556-560.
16. Hibberd ML, Sumiya M, Summerfield JA, Booy R, Levin M. Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease. Meningococcal Research Group. Lancet 1999; 353: 1049-1053.
17. Roy S, Hill AV, Knox K, Griffiths D, Crook D. Research pointers: association of common genetic variant with susceptibility to invasive pneumococcal disease. BMJ 2002; 324: 1369.
18. Roy S, Knox K, Segal S et al. MBL genotype and risk of invasive pneumococcal disease: a case-control study. Lancet 2002; 359: 1569-1573.
19. Tracey KJ, Lowry SF, Fahey III TJ et al. Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg Gynecol Obstetr 1987, 164: 415-422.
20. Tracey KJ, Beutler B, Lowry SF et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234 470-474.
21. Girardin E, Grau GE, Dayer JM, Roux-Lombard R, Lambert PH. Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med 1988; 319: 397-400.
22. Waage A, Halstensen A, Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987; 1: 355-357.
23. Stuber F, Udalova IA, Book M et al. -308 tumor necrosis factor (TNF) polymorphism is not associated with survival in severe sepsis and is unrelated to lipopolysaccharide inducibility of the human TNF promoter. J Inflamm 1996; 46: 42-50.
24. O'Keefe GE, Hybki DL, Munford RS. The G→A single nucleotide polymorphism at the -308 position in the tumor necrosis factor-alpha promoter increases the risk for severe sepsis after trauma. J Trauma 2002; 52: 817-825.
25. Tang GJ, Huang SL, Yien HW et al. Tumor necrosis factor gene polymorphism and septic shock in surgical infection. Crit Care Med 2000; 28: 2733-2736.
26. Waterer GW, Quasney MW, Cantor RM, Wunderink RG. Septic shock and respiratory failure in community-acquired pneumonia have different TNF polymorphism associations. Am J Resp Crit Care Med 2001; 163 1599-1604.
27. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 1997; 94: 3195-3199.
28. Brinkman BM, Zuijdeest D, Kaijzel EL, Breedveld FC, Verweij CL. Relevance of the tumor necrosis factor alpha (TNF alpha) -308 promoter polymorphism in TNF alpha gene regulation. J Inflamm 1995; 46: 32-41.
29. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci USA 1992; 89: 4845-4849.
30. McDermott MF, Aksentijevich I, Galon J et al. Germline mutations in the extracellular domains of the 55 kDa receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndrome. Cell 1999; 97: 133-144.
31. Komata T, Tsuchiya N, Matsushita M, Hagiwara K, Tokunaga K. Association of tumor necrosis factor receptor 2 (TNFR2) polymorphism with susceptibility to systemic lupus erythematosus. Tissue Antigens 1999; 53: 527-533.
32. Morita C, Horiuchi T, Tsukamoto H et al. Association of tumor necrosis factor receptor type II polymorphism 196R with systemic lupus erythematosus in the Japanese: molecular and functional analysis. Arthritis Rheum 2001; 44: 2819-2827.
33. Sashio H, Tamura K, Ito R et al. Polymorphisms of the TNF gene and the TNF receptor superfamily member 1B gene are associated with susceptibility to ulcerative colitis and Crohn's disease, respectively. Immunogenetics 2002; 53: 1020-1027.
34. Moreno R, Vincent JL, Matos R et al. The use of maximum SOFA score to quantify organ dysfunction/ failure in intensive care. Results of a prospective, multicentre study. Working Group on Sepsis related Problems of the ESICM. Intensive Care Med 1999; 25: 686-696.
35. Colhoun HM, McKeigue PM, Davey SG. Problems of reporting genetic associations with complex outcomes. Lancet 2003; 361: 865-872.
36. Bayley J-P, Ottenhoff THM, Verweij CL. Is there a future for TNF promoter polymorphisms? Genes Immun 2004, advance online publication - doi:10.1038/sj.gene.6364055.
37. Peters DL, Barber RC, Flood EM, Garner HR, O'Keefe GE. Methodologic quality and genotyping reproducibility in studies of tumor necrosis factor -308 G→A single nucleotide polymorphism and bacterial sepsis: implications for studies of complex traits. Crit Care Med 2003; 31: 1691-1696.
38. Carroll MC, Katzman R, Alicot EM et al. Linkage map of the human major histocompatibility complex including the tumor necrosis factor genes. Proc Natl Acad Sci USA 1987; 84: 8535-8539.
39. Fabris M, Di PE, D'Elia A, Damante G, Sinigaglia L, Ferraccioli G. Tumor necrosis factor-alpha gene polymorphism in severe and mild-moderate rheumatoid arthritis. J Rheumatol 2002; 29: 29-33.
40. Huizinga TW, Westendorp RG, Bollen EL et al. TNF-alpha promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients. J Neuroimmunol 1997; 72: 149-153.
41. Ferencik S, Lindemann M, Horsthemke B, Grosse-Wilde H. A new restriction fragment length polymorphism of the human TNF-B gene detected by AspHI digest. Eur J Immunogenet 1992; 19: 425-430.
42. Knight JC, Keating BJ, Rockett KA, Kwiatkowski DP. In vivo characterization of regulatory polymorphisms by allele-specific quantification of RNA polymerase loading. Nat Genet 2003; 33: 469-475.
43. Ozaki K, Ohnishi Y, Iida A et al. Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet 2002; 32: 650-654.
44. Ackerman HC, Ribas G, Jallow M et al. Complex haplotypic structure of the central MHC region flanking TNF in a West African population. Genes Immun 2003; 4: 476-486.
45. Cardon LR, Palmer LJ. Population stratification and spurious allelic association. Lancet 2003; 361: 598-604.
46. American College of Chest Physicians /Society of Critical Care Medicine. Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864-874.
47. Zhang DL, Li JS, Jiang ZK Yu BJ, Tang XM. Association of two polymorphisms of tumor necrosis factor gene with acute severe pancreatitis. J Surg Res 2003; 112: 138-143.
48. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992; 175: 323-329.
49. Froon AH, Bemelmans MH, Greve JW, van der Linden CJ, Buurman WA. Increased plasma concentrations of soluble tumor necrosis factor receptors in sepsis syndrome: correlation with plasma creatinine values. Crit Care Med 1994; 22: 803-809.
50. Geurts JM, Janssen RG, van Greevenbroek MM et al. Identification of TNFRSF1B as a novel modifier gene in familial combined hyperlipidemia. Hum Mol Genet 2000; 9: 2067-2074.
51. Girardin E, Roux-Lombard P, Grau GE, Suter P, Gallati H, Dayer JM. Imbalance between tumour necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia. The J5 Study Group. Immunology 1992; 76: 20-23.
52. Pellegrini JD, Puyana JC, Lapchak PH, Kodys K, Miller-Graziano CL. A membrane TNF-alpha/TNFR ratio correlates to MODS score and mortality. Shock 1996; 6: 389-396.
53. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-829.
54. McCabe WR, Jackson GG. Gram-negative bacteremia. Arch Intern Med 1962; 110: 847-855.
55. Vincent J-L, Moreno R, Takala J et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med 1996; 22: 710.
56. Pantelidis P, Lympany PA, Foley PJ, Fanning GC, Welsh KI, Du Bois RM. Polymorphic analysis of the high-affinity tumor necrosis factor receptor 2. Tissue Antigens 1999; 54: 585-591.
57. Grutters JC, Sato H, Pantelidis P et al. Increased frequency of the uncommon tumor necrosis factor -857T allele in British and Dutch patients with sarcoidosis. Am J Resp Crit Care Med 2002; 165: 1119-1124.
58. Fanning GC, Bunce M, Black CM, Welsh KI. Polymerase chain reaction haplotyping using 3′ mismatches in the forward and reverse primers: application to the biallelic polymorphisms of tumor necrosis factor and lymphotoxin alpha. Tissue Antigens 1997; 50: 23-31.
59. Zhao JH, Curtis D, Sham PC. Model-free analysis and permutation tests for allelic associations. Hum Hered 2000; 50 133-139.